Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
1. A cartilage substitute comprising a blood plasma-derived plastic, wherein the blood plasma-derived plastic comprises at least partially dried clotted blood plasma, wherein the clotted blood plasma comprises whole plasma, including a plasma clot and serum.
2. The cartilage substitute of claim 1 , wherein the blood plasma-derived plastic comprises one or more of a plasticizer, stabilizer, drug or other therapeutic, filler, porogen, crosslinker, biological response modifier, polymeric material, tracer, labeled compound, and metal ion.
3. The cartilage substitute of claim 2 , wherein the blood plasma-derived plastic comprises the biological response modifier, and the biological response modifier is a bioactive protein selected from the group consisting of hormones, growth factors, cytokines, extracellular matrix molecules, and mixtures thereof.
4. The cartilage substitute of claim 3 , wherein the blood plasma-derived plastic comprises at least one biological response modifier that is heat-sensitive.
5. The cartilage substitute of claim 3 , wherein the biological response modifier is a bioactive protein and the bioactive protein comprises at least one growth factor selected from the group consisting of platelet derived growth factors (PDGF), acidic and basic fibroblast growth factors, transformation growth factor beta (TGF-beta), insulin like growth factors (IGF), epidermal growth factors (EGF), platelet-derived angiogenesis factors (PDAF), platelet-derived endothelial growth factors (PDEGF), tumor necrosis factor-alpha (TNF-α), tumor necrosis factor-beta (TNF-β), vascular endothelial growth factors (VEGF), epithelial cell growth factors (ECGF), granulocyte-colony stimulating factors (G-CSF), granulocyte-macrophage colony stimulating factors (GM-CSF), nerve growth factors (NGF), neurotrophins, erythropoietin (EPO), thrombopoietin (TPO), myostatin (GDF-8), growth differentiation factor-9 (GDF9), hepatocyte growth factors (HGF), platelet factors, and mixtures thereof.
6. The cartilage substitute of claim 3 , wherein the biological response modifier is a bioactive protein and the bioactive protein comprises at least one extracellular matrix molecule selected from the group consisting of osteocalcin, osteonectin, fibrinogen, vitronectin, fibronectin, thrombospondin 1 (TSP-1), bone sialoprotein (BSP), proteoglycans and mixtures thereof.
7. The cartilage substitute of claim 2 , wherein the blood plasma-derived plastic comprises the plasticizer, and the plasticizer is selected from the group consisting of water, glycerol, and mixtures thereof.
8. The cartilage substitute of claim 7 , wherein the plasticizer is glycerol.
9. The cartilage substitute of claim 2 , wherein the blood plasma-derived plastic comprises the crosslinker, and the crosslinker is selected from the group consisting of carbodiimides, Factor XIII, dihomo bifunctional NHS esters, genipin, and mixtures thereof.
10. The cartilage substitute of claim 9 , wherein the crosslinker is genipin.
11. The cartilage substitute of claim 2 , wherein the blood plasma-derived plastic comprises the drug, and the drug is selected from the group consisting of analgesics; anti-infective agents; antineoplastics; biologicals; blood modifiers; cardioprotective agents; cardiovascular agents; cholinesterase inhibitors; hormones; immunomodulators; immunosuppressives; ophthalmic preparations; respiratory agents; anti-inflammatory agents; skin and mucous membrane agents; anti-cancer agents; and mixtures thereof.
12. The cartilage substitute of claim 2 , wherein the blood plasma-derived plastic comprises the porogen, and the porogen is soluble in an aqueous phase.
13. The cartilage substitute of claim 1 , wherein the blood plasma-derived plastic comprises pores.
14. The cartilage substitute of claim 1 , wherein the cartilage substitute is pliant, elastic, or a combination thereof.
15. The cartilage substitute of claim 1 , wherein the cartilage substitute is rigid.
16. The cartilage substitute of claim 1 , wherein the cartilage substitute comprises a gradient of physical or chemical characteristics.
17. The cartilage substitute of claim 16 , wherein the cartilage substitute comprises the gradient of physical characteristics, and the physical characteristics are selected from the group consisting of one or more of density, porosity, elasticity and tensile strength.
18. The cartilage substitute of claim 16 , wherein the cartilage substitute comprises the gradient of chemical characteristics, and the chemical characteristics comprise a variation in the concentration of one or more agents.
19. The cartilage substitute of claim 18 , wherein the one or more agents are selected from the group consisting of a plasticizer, stabilizer, growth factor, drug or other therapeutic, filler, porogen, crosslinker, biological response modifier, polymeric material, tracer, labeled compound, and metal ion.
20. The cartilage substitute of claim 16 , wherein the cartilage substitute has more than one physical gradient, more than one chemical gradient, or at least one physical gradient and at least one chemical gradient.
21. The cartilage substitute of claim 1 , wherein the blood plasma-derived plastic comprises one or more of surface textures, roughened spots, pores, and holes.
22. The cartilage substitute of claim 1 , wherein the cartilage substitute has a Young's Modulus ranging from about 1 MPa to about 250 MPa.
23. The cartilage substitute of claim 1 , wherein the cartilage substitute has a percent strain at failure ranging from about 0.1% to about 1%.
24. The cartilage substitute of claim 1 , wherein the cartilage substitute has a stiffness ranging from about 5 N/mm to about 4000 N/mm.
25. The cartilage substitute of claim 1 , wherein the cartilage substitute comprises a cell seeded in or on the substitute.
26. The cartilage substitute of claim 25 , wherein the cell is a stem cell.
27. The cartilage substitute of claim 26 , wherein the stem cell is an embryonic, adult, autologous, allogenic, or xenogenic stem cell.
28. The cartilage substitute of claim 1 , further comprising one or more microbarbs.
29. The cartilage substitute of claim 1 , wherein the blood plasma-derived plastic retains biological activity.
30. The cartilage substitute of claim 1 , wherein the whole plasma is obtained from an autologous donor.
31. The cartilage substitute of claim 1 , wherein the whole plasma is obtained from allogeneic donors.
32. The cartilage substitute of claim 1 , wherein the at least partially dried clotted blood plasma is essentially fully dried.
33. The cartilage substituted of claim 1 , wherein the platelet concentration of the whole plasma in the blood plasma-derived plastic is increased compared to a baseline platelet concentration of whole plasma.
34. A cartilage filler comprising a blood plasma-derived plastic, wherein the blood plasma-derived plastic comprises at least partially dried clotted plasma, wherein the clotted blood plasma comprises whole plasma, including a plasma clot and serum.
35. A cartilage substitute comprising a blood plasma-derived plastic, wherein the blood plasma-derived plastic comprises at least partially dried clotted blood plasma, wherein the clotted blood plasma comprises whole plasma, including a plasma clot and serum, wherein the cartilage substitute is prepared by a method comprising:
a) clotting a quantity of whole plasma to form clotted blood plasma, wherein the clotted blood plasma comprises the whole plasma, including a plasma clot and serum;
b) at least partially drying the clotted blood plasma to form the at least partially dried clotted blood plasma;
c) contacting a quantity of the at least partially dried clotted blood plasma with at least one plasticizer to make a bioplastic dough; and
d) shaping and heating the bioplastic dough to make the cartilage substitute.
36. The cartilage substituted of claim 35 , wherein the platelet concentration of the whole plasma in the blood plasma-derived plastic is increased compared to a baseline platelet concentration of whole plasma.